NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: VolitionRx's Nu.Q NETs Assay in France's National Sepsis Detection Initiative
TL;DR
VolitionRx's Nu.Q NETs H3.1 assay was selected for a €6.3 million French government program, giving the company a competitive edge in early sepsis detection technology.
Volition's biomarker assay works by detecting H3.1 levels in blood, delivering results within one hour on automated analyzers to identify sepsis severity and predict outcomes.
This technology could save lives by enabling earlier sepsis detection, improving patient outcomes and reducing healthcare burdens through better emergency care decisions.
A single blood test now outperforms established severity scores in predicting sepsis outcomes, potentially transforming emergency medicine with rapid, automated biomarker analysis.
Found this article helpful?
Share it with your network and spread the knowledge!
VolitionRx Ltd.'s Nu.Q® NETs H3.1 assay has been chosen as the sole biomarker for DETECSEPS, a French government-funded evaluation of early sepsis detection under the France 2030 plan.
The H3.1 biomarker is highly correlated with disease severity and provides excellent prognostic utility for outcomes like organ failure and mortality, potentially improving early identification of sepsis in emergency settings when combined with clinical scores.
According to Professor Djillali Annane, the H3.1 biomarker's prognostic power at ICU admission significantly exceeded established severity scores such as APACHE II and SOFA.
Volition's biomarker can deliver results within one hour on the Immunodiagnostic Systems (IDS) i10® automated analyzer, potentially enhancing emergency decision-making.
The program is led by the IHU SEPSIS and supported by a €6.3 million (~$7.3 million) grant, with Professor Djillali Annane from the Intensive Care Department, IHU SEPSIS, Raymond Poincaré Hospital (AP-HP) serving as Scientific Director.
Volition believes that through earlier identification of sepsis, lives can be saved, the quality of life of survivors can be improved, and the burden on healthcare systems can be reduced.
Volition is a multi-national epigenetics company focused on developing simple, cost-effective blood tests to help detect and monitor diseases including cancers and diseases associated with NETosis, such as sepsis.
Volition is providing the Nu.Q® H3.1 Assay pro-bono to enable this important evaluation of early sepsis detection.
For further information, visit the company's website at www.Volition.com.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
Curated from InvestorBrandNetwork (IBN)
